Research programme: BET bromodomain inhibitors - Nuevolution

Drug Profile

Research programme: BET bromodomain inhibitors - Nuevolution

Alternative Names: NUE 7770; NUE007770-7

Latest Information Update: 24 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nuevolution
  • Class Small molecules
  • Mechanism of Action BRD1 protein inhibitors; Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Arthritis; Idiopathic pulmonary fibrosis; Inflammation; Systemic lupus erythematosus

Most Recent Events

  • 19 Jun 2017 Positive pharmacodynamics data from a preclinical study in Systemic lupus erythematosus released by Nuevolution
  • 05 Oct 2016 Research programme: BET bromodomain inhibitors - Nuevolution is available for licensing as of 05 Oct 2016. https://nuevolution.com/
  • 01 Jan 2015 Preclinical trials in Systemic lupus erythematosus, Idiopathic pulmonary fibrosis, Inflammation and Arthritis in Denmark (PO) (Nuevolution annual report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top